RET polymorphisms in codons 769 and 836 are not associated with predisposition to medullary thyroid carcinoma

Cancer Detection and Prevention
Małgorzata WienchB Jarzab

Abstract

The study was undertaken to verify whether the RET gene polymorphisms are associated with MTC in patients negative for germline mutations. Two hundred five patients with apparent sporadic MTC were subjected to genetic analysis of RET exons 10, 11, 13, 14, 16 and 22 RET germline mutation carriers were identified with 10.7% frequency. The frequency among 26 patients not older than 30 was 27%. In patients excluded for known mutations we analyzed two polymorphic sites: RET codon 769 and 836. As control group, 90 healthy subjects were investigated. In young patients the observed allelic frequencies were 32% for variant L769/CTG and 5% for variant S836/AGT. Although these values were higher than in older MTC patients (22 and 3%, respectively), as well as in the control group (27 and 2%) the difference was insignificant. We conclude that in Polish patients polymorphisms at RET codons 769 and 836 are not associated with medullary thyroid carcinoma.

References

Jul 29, 1998·Journal of Internal Medicine·G RomeoG Martucciello
May 29, 2000·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·D K BartschW Höppner
Jan 10, 2001·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·C A KochK Pacak
Apr 30, 2002·International Journal of Cancer. Journal International Du Cancer·Laura GilJosé M Rojas
Dec 20, 2002·Thyroid : Official Journal of the American Thyroid Association·Salud BorregoGuillermo Antiñolo
Jan 10, 2003·The Journal of Clinical Endocrinology and Metabolism·Steve C HuangZhengping Zhuang
Jul 9, 2004·The Journal of Clinical Endocrinology and Metabolism·Rossella EliseiAldo Pinchera

❮ Previous
Next ❯

Citations

Feb 21, 2006·Thyroid : Official Journal of the American Thyroid Association·I M GuerreroE R P Gimba
Feb 12, 2011·Thyroid : Official Journal of the American Thyroid Association·Ehsan AlvandiMehrdad Pedram
Jul 4, 2006·Molekuliarnaia biologiia·N V SeverskaiaS Iasmita
May 26, 2011·Journal of Molecular Endocrinology·Iñigo Landa, Mercedes Robledo
Dec 23, 2006·Journal of Endocrinological Investigation·A GursoyG Erdogan
Feb 3, 2007·Journal of Pediatric Surgery·Samuel W MooreMonique G Zaahl
Feb 21, 2008·Clinical Endocrinology·Laura FugazzolaLuca Persani
Apr 5, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yuanqi ZhangJianwen Li
Jun 23, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James M ClearyLori J Wirth
Jan 23, 2008·Arquivos brasileiros de endocrinologia e metabologia·Marcelo A C G dos SantosSergio Pereira de A Toledo
Sep 28, 2017·Thyroid : Official Journal of the American Thyroid Association·Maylis LebeaultDelphine Mirebeau-Prunier
Aug 25, 2005·The Journal of Clinical Endocrinology and Metabolism·S M Baumgartner-ParzerH Vierhapper
Jul 20, 2006·Endocrine Reviews·Jan Willem B de GrootRobert M W Hofstra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.